Representativeness of the participants in the smoking Cessation in Pregnancy Incentives Trial (CPIT): A cross-sectional study by Bessing, Barnabas et al.
RESEARCH Open Access
Representativeness of the participants in
the smoking Cessation in Pregnancy
Incentives Trial (CPIT): a cross-sectional
study
Barnabas Bessing1, Linda Bauld2, Lesley Sinclair2, Daniel F. Mackay3, William Spence4 and David M. Tappin5*
Abstract
Background: The limited representativeness of trial samples may restrict external validity. The aim of this study was to
ascertain the representativeness of the population enrolled in the Cessation in Pregnancy Incentives Trial (CPIT), a
therapeutic exploratory study to examine the effectiveness of financial incentives for smoking cessation during
pregnancy.
Methods: CPIT participants (n = 492) were compared with all self-reported smokers at maternity booking who did not
participate in the trial (n = 1982). Both groups were drawn from the National Health Service (NHS) Greater Glasgow and
Clyde area over a 1-year trial enrolment period. Variables used for comparison were age, area-based deprivation index,
body mass index, gestation, and carbon monoxide (CO) breath test level. Chi-square and Mann-Whitney U tests were
used to compare groups.
Results: From January to December 2012, 2474/13,945 (17.7 %) women, who booked for maternity care, self-reported
as current smokers (at least one cigarette in the last week). Seven hundred and fifty-two were ineligible for trial
participation because of a CO breath test level of less than 7 parts per million (ppm) used as a biochemical cut-off to
corroborate self-report of current smoking. At telephone consent 301 could not be contacted, 11 had miscarried, 16
did not give consent and 3 opted out after randomisation, leaving 492 participants for analysis. There were no
differences in demographic or clinical characteristics between trial participants, and self-reported smokers not enrolled
in the trial in terms of CO breath test (as a measure of smoking level for those with a CO level of 7 ppm or higher),
material deprivation (using an area-based measure), maternal age and maternal body mass index. Gestation at booking
was statistically significantly lower for participants.
Conclusions: To ensure that all trial participants were smokers, biochemical validation excluded self-reported smokers
with a CO level of less than 7 ppm from taking part in the trial, which excluded 30 % of self-reported smokers who
were ‘lighter’ smokers. The efficacy of financial incentives would not have been likely to decrease if ‘lighter’ smokers
had been included in the trial population. Trial participants were slightly earlier in their pregnancy at maternity
booking, but this difference would not clinically affect the provision of financial incentives if provided routinely. Overall,
the trial population was representative of all self-reported smokers with regard to available routinely collected data.
Appropriate comparison of trial and target populations, with detailed reporting of exclusion criteria would contribute
to the understanding of the wider applicability of trial results.
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Background
The fundamental evidence for decision-making in patient
care has in the past been based on clinical experience [1].
More recently, clinicians and decision-makers have come
to accept that rigorous research is required in addition to
experience [2] in order to tackle growing population
health challenges. Current intervention protocols and clin-
ical guidelines combine high-quality research from indi-
vidual patient treatment [3] with clinical experience.
Randomised controlled trials (RCTs) with reliable internal
validity are considered the ‘gold standard’ [4] to inform
decision-making for both individual patients and popula-
tion health [5–7]. Guidelines to help clinicians make quick
but accountable decisions should be guided by accurate
and reliable research findings from RCTs [3] to minimise
bias. However, trial findings must benefit the target group
with similar therapeutic needs (external validity) [4]. Clini-
cians [8–10] have questioned the effectiveness and reli-
ability of applying trial evidence to target populations
outside a trial setting. This may explain delayed use of trial
evidence in clinical practice [10, 11]. In the USA, a large
body of research has been reviewed showing that ethnic
minority groups are under-represented in trials [12].
Much of this review focussed on reasons why ethnic mi-
nority groups are more difficult to access and are less
likely to agree to take part and be retained in research
studies. There are many plausible reasons, but in general
trials have insufficient representation from ethnic minority
groups for clinicians to feel confident that the trial results
should lead to change in treatment for those groups.
Trial selection criteria [6, 13, 14] and overall method-
ology to ensure internal validity may threaten representa-
tiveness. For instance, patients with comorbid conditions
are often excluded from trials. In subsequent clinical prac-
tice, beneficial effects may not be realised perhaps due to
side effects associated with a common comorbid condition
that is highly represented in the target population. It is
important, therefore, to compare trial participants with
the target population with regard to demographic, clinical
and other variables. Such comparison will help to uncover
possible bias associated with nonrepresentative trial popu-
lations and allow a judgement to be made about the likely
generalisability of trial results [4, 15]. Models of reasons
for taking part and not taking part are important [16] to
try to understand how better to run research projects that
are representative and, therefore, produce results
applicable to all groups in the target population. However,
this present study did not attempt to understand the rea-
sons behind lack of representativeness, but was limited to
establishing representativeness or not, using limited
criteria available from both the trial population and the tar-
get population from which the trial population was drawn.
The Cessation in Pregnancy Incentives Trial (CPIT)
[17, 18] was a therapeutic exploratory phase II trial to
examine the efficacy and acceptability of using financial
incentives to help pregnant smokers to make use of rou-
tine Stop Smoking Services (SSS) and or quit smoking
during pregnancy. Women were eligible if they were
self-reported smokers with an exhaled carbon monoxide
level of at least 7 parts per million (ppm) (to biochem-
ically demonstrate current smoking), aged 16 years or
older (for consent), less than 24 weeks pregnant (to
allow intervention lasting 12–16 weeks by SSS), resident
in NHS Greater Glasgow and Clyde (to allow access for
research nurses to collect biochemical verification mea-
sures of smoking cessation), and able to understand and
speak English (for telephone consent). This study used
492 trial participants of 2494 (20 %) women who self-
reported as current smokers (at least one cigarette in the
last week) at their first maternity booking contact ap-
pointment – the target population. The trial showed the
intervention to be effective [18] and cost-effective [19];
however, there remains a valid question: ‘Is the interven-
tion likely to be effective if applied to the whole target
population?’
Comparisons were, therefore, made between self-
reported pregnant smokers not included in the trial or
without analysable data (group B; Fig. 1) and trial partici-
pants enrolled in CPIT with analysable data (group A;
Fig. 1) [17, 18]. Together these groups make up the target
population for the intervention. The findings will help
policy-makers to determine the representativeness of the
trial population and the likely generalisability of financial
incentives for smoking cessation during pregnancy.
Methods
The design of this representativeness study was cross-
sectional, comparing the trial population with self-
reported pregnant smokers not included in the trial in
terms of available routinely collected demographic and
clinical data. The setting was maternity booking in
early pregnancy in NHS Greater Glasgow and Clyde
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in the West of Scotland where all pregnant women
are routinely asked about their smoking status and a
CO breath test is administered as an objective proxy
measure of smoking status – about 97 % of pregnant
women at first maternity booking in Greater Glasgow
and Clyde undergo this test [20]. Client details, in-
cluding self-reported smoking status and CO level are
forwarded using an opt-out approach from the mater-
nity booking appointment to the NHS SSS as recom-
mended in national guidelines [21]. The SSS then
telephones all pregnant smokers to discuss smoking
and attempting to quit. During this contact, verbal
permission was obtained from eligible potential trial
participants to pass their contact details to the trial
team. Ineligible pregnant smokers were those: with a
CO breath test level less than 7 ppm or where no
CO breath test level was available; where no contact
was possible by the SSS; who were under 16 years of
age; who were at 24 full weeks gestation or more at
maternity booking (to allow SSS support to take place
prior to expected delivery); who were not approached
by SSS about the trial; who did not speak English;
and who refused permission to pass contact details to
the research team. The trial team attempted to con-
tact pregnant smokers to discuss trial participation
and a few who were contacted were no longer preg-
nant. The remaining patients were asked for verbal
consent to take part in the trial. Those who agreed to
take part were enrolled into the trial.
Group A are trial participants (n = 492). Group B are
self-reported smokers at maternity booking who were
not included in the trial when analysed (n = 1982).
Variables used to compare group A with group B
Variables from the two population groups were gathered
from routinely collected maternity service data: CO
breath test level, height, weight, postcode, age and ge-
station. Gestation was recorded as estimated gestation
(in weeks calculated from recall of last menstrual period)
at the date of referral to the SSS and ranged from 4 to
40 weeks. Body mass index (BMI) was derived from
maternal height and weight using the formula;
Wt in kilosð Þ=Ht2 in metresð Þ:
Finally, material deprivation was measured using the
Scottish Index of Multiple Deprivation (SIMD) [22] with
postcode as proxy. ‘SIMD ranks small areas (called data-
zones) from most deprived (ranked 1) to least deprived
(ranked 6505) using 38 indicators from seven domains;
income, employment, health, education, skills and train-
ing, housing, geographic access and crime’ [22]. In order
to compare the CO levels (and, therefore, heaviness of
smoking [23]) between those enrolled in the trial and
2474 (100% of self-reported smokers)
301 (12%) Trial team unable to contact
5 (<1%) miscarriage prior to contact
Contacted by trial team
517 (21% of self-reported smokers)
Recruited to trial
495 (20% of self-reported smokers)
Group A:
Self-reported smokers enrolled into
the trial with analysable data
492
Group B: 
Self-reported smokers NOT enrolled into 
the trial or without analysable data
1982
Eligible and passed to trial team
823 (33% of self-reported smokers)
Not eligible or not contactable by SSS
1651 (67% of self-reported smokers)1
16 (<1%) Consent not given
6 (<1%) miscarriage
3 (<1%) Opted out after consent with no analysable data
Fig. 1 Study sampling frame and sample. Two thousand four hundred and seventy-four women between January and December 2012 replied ‘Yes’
when asked by their midwife at their maternity booking visit if they had smoked at least one cigarette in the last week. Seven hundred and fifty-two
had a carbon monoxide level (CO) less than 7 ppm, or unavailable in 172 (7 %); 13 (<1 %) were under 16 years of age; 243 (10 %) had a gestation
≥24 weeks; 593 (24 %) were not contactable by the Stop Smoking Service (SSS); 23 (<1 %) were non-English speaking; the trial was not discussed by
the SSS with 31 (1 %); and permission was not obtained to pass contact details for 113 (5 %). These categories are not mutually exclusive. The
remaining 823 (33 % of all self-reported smokers) were eligible for the trial and were passed to the trial team. A records check showed that five had
miscarried and contact was not attempted. Three hundred and one could not be contacted by the trial team. Of the 517 contacted, 6 had miscarried
and 16 did not consent to the trial. Of the 495 who consented and were randomised, 3 control participants opted out and did not want any data
collected in the trial to be used leaving 492 trial participants with data for analysis making up group A. All self-reported smokers who were not
included in the trial analysis (2474–492) made up group B (n = 1982)
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those who chose or could not be enrolled in the trial,
comparison between groups A and B was made after ex-
cluding those with a CO level less than 7 ppm. The aim
was to show that apart from the exclusion criterion of a
CO level less than 7 ppm the groups were similar in
heaviness of smoking.
Statistical analyses
Statistical analyses were performed with Stata 12.10 [24].
Descriptive statistics (percentages, medians and inter-
quartile ranges) were derived for all variables. Univariate
statistical comparison used Pearson X2 test for linear
trend and Mann-Whitney U tests to ascertain possible
group differences between group B – self-reported
smokers not included in the trial and group A – the trial
participants. We used multivariable logistic regression to
control for the possible effects of confounding among
our variables. Nonlinearities for continuous variables
were tested using polynomial terms.
Results
Study setting and sample characteristics
Of the women who booked for maternity care, 2474/
13,945 (17.7 %) were self-reported smokers, 172 (7.0 %)
were excluded from all analyses because their CO level
was missing or unknown, 752 (30.4 %) were excluded
because their CO level was below 7 ppm, and 727
(29.4 %) did not meet the other inclusion criteria (Fig. 1).
After checking routine records, 5 (<1 %) had miscarried
and, therefore, contact was not attempted, and for 301
(12 %) contact was unsuccessful. Out of the 517 women
contacted, consent for enrolment in the trial was not
given by 16 women, 6 had miscarried, and the remaining
495 were enrolled. Three participants withdrew, refusing
permission for their data to be used, leaving 492 trial
participants’ data for analysis (Fig. 1) as group A. Those
not included in the trial, 1982 (2474 − 492), made up the
comparison group B.
Comparison of groups
The median CO breath test result for both self-
reported smokers at maternity booking not included
in the trial (excluding those with a CO level less than
7 ppm) and the trial participants was 12 ppm (Table 1).
A statistically significant difference (P < 0.001) was
seen for gestation at booking with those in the trial
booking at slightly earlier gestation (median 12.9 weeks
compared with 13.3 weeks for those not included in
the trial).
Table 2 shows the odds ratios for a multivariable logis-
tic regression of trial status on gestation, age category,
deprivation category and BMI category. All variables
with the exception of estimated gestation are not statisti-
cally significant. The effect of estimated gestation is that
of increasing the odds into the trial. However, the square
term shows that at higher gestational ages the odds of
being in the trial declines significantly, P = 0.007.
Discussion
Comparing trial participants and self-reported smokers
not included in the trial
Overall, there was no evidence from available rou-
tinely collected demographic or clinical characteristics
that trial participants differed in a way that would
make a difference to implementation or effectiveness
of the incentives intervention. This suggests that the
trial sample was representative of the whole target
population of self-reported smokers identified at
Table 1 Summary of baseline characteristics of nontrial (group
B) and trial (group A) groups taken from all self-reported
smokers at maternity booking from January to December 2012
Characteristics Nontrial
group B
(n = 1982)
Trial
group A
(n = 492)
P value
CO level (ppm) for those
with CO ≥7 ppm, median
(interquartile range)
12 (10–16) 12 (10–17) 0.98
Gestation (weeks), median
(interquartile range)
13.3 (11.7–15.3) 12.9 (11.3–14.3) <0.001a
Deprivation quintiles, n (%)
Most deprived
1st 1331 (67.4) 322 (65.5) 0.58b
2nd 319 (16.2) 83 (16.9)
3rd 168 (8.5) 51 (10.4)
4th 100 (5.1) 21 (4.3)
5th 56 (2.8) 15 (3.1)
Least deprived
Missing 8 0
Age under 20 272 (13.7) 59 (12.0) 0.09c
20–24 599 (30.3) 126 (25.6)
25–29 491 (24.8) 136 (27.6)
30–34 359 (18.1) 113 (23.0)
35+ 258 (13.0) 58 (11.8)
Missing 3 0
BMI categories, n (%)
Underweight 90 (4.6) 19 (4.0) 0.15d
Normal weight 921 (47.5) 215 (44.7)
Overweight 532 (27.5) 139 (28.9)
Obese 395 (20.4) 108 (22.5)
Missing 44 11
aMann-Whitney U test
bChi-square test of trend
cChi-square test of trend
dChi-square test of trend
BMI body mass index, CO carbon monoxide
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maternity booking in NHS Greater Glasgow and
Clyde (Table 1). This is similar to randomised con-
trolled trial studies in cannabis dependence [25] and
also in smoking and chewing tobacco cessation trials
[26, 27] none of which were among pregnant women.
However, other studies [28, 29] found their trial pop-
ulations to be nonrepresentative in terms of demo-
graphic and clinical characteristics. Evidence from
systematic reviews [8, 30] indicates that pharmaceut-
ical trials often exclude the majority of patients based
on age, comorbidity, multiple drug use and other
unexplained reasons, resulting in nonrepresentative
samples. Our results indicate that the CPIT popula-
tion was a representative sample of all self-reported
smokers identified at first maternity booking contact
visit (the target population) in NHS Greater Glasgow
and Clyde Health Board area.
An exhaled CO level of less than 7 ppm excluded 30 %
of self-reported smokers. The aim was to make sure that
all participants were smokers rather than nonsmokers
masquerading as smokers to try to receive incentive pay-
ments. A previous study in the same geographical area
[31], before the incentives trial, showed that 36 % of self-
reported smokers at maternity booking (with no advan-
tage gained by calling themselves smokers) had a CO
level of less than 7 ppm. It therefore seems likely that
self-reported smokers who were excluded because their
CO breath test gave a reading less than 7 ppm were true
smokers but light smokers [23]. Light smokers are more
likely to successfully quit with effective support [32].
Therefore, excluding these women is not likely to have
overestimated the true effectiveness of financial incen-
tives if offered to all self-reported smokers identified at
maternity booking.
Gestation was significantly different with self-reported
smokers who were not included in the trial, having a
higher gestation at maternity booking of 13.3 weeks
compared to trial participants’ 12.9 weeks. However, this
difference is small and likely to be skewed by the few
women who book late during pregnancy as women with
greater than 24 weeks gestation at maternity booking
were also excluded. This difference in gestation between
groups A and B would not be large enough to affect im-
plementation of financial incentives if they were rolled
out across the health board area.
Achieving representativeness and external validity
alongside internal validity is a difficult task especially in
clinical trials. This study, using data from a novel trial
for smoking cessation in pregnancy, showed that rou-
tinely collected data from maternity booking can provide
large general target and trial population groups for ad-
equate comparison, essential when assessing representa-
tiveness. Data items available for this study were by no
means exhaustive, but those available show that partici-
pants were of similar age, material deprivation status,
heaviness of smoking addiction and gestation to those
women who did not take part from the target popula-
tion. Therefore, it seems likely that an effective smoking
cessation intervention demonstrated among trial partici-
pants would be generalisable to the whole of the target
population of pregnant smokers identified at the first
maternity booking visit.
Limitations of the study
Consideration of other important covariates with regard
to representativeness of the trial population which were
not available – such as marital status, education, partner
smoking status, employment, symptoms of psychological
distress, and others known to influence smoking during
pregnancy – may have produced different results.
Reasons why the study population might not be repre-
sentative such as ‘program benefits’ and ‘barriers to par-
ticipation’ [16] were not considered but are of great
importance when beginning to design a public health
intervention strategy and through the stages of testing the
intervention – pilot, definitive trial and implementation.
Table 2 Odds ratios (ORs) for a multivariable logistic regression
of trial status on gestation, age category, deprivation category
and body mass index (BMI) category
Characteristics OR (95 % CI) P value
Gestation (weeks) 1.12 0.122
Gestation (squared) 0.99 0.007
Deprivation quintiles, n (%)
Most deprived
1st 1.0
2nd 1.13 (0.86, 1.49) 0.383
3rd 1.25 (0.89, 1.77) 0.201
4th 0.81 (0.50, 1.33) 0.416
5th 1.08 (0.59, 1.96) 0.806
Least deprived
Age
under 20 1.0
20–24 0.91 (0.64, 1.29) 0.590
25–29 1.20 (0.85, 1.71) 0.301
30–34 1.34 (0.93, 1.93) 0.117
35+ 1.10 (0.72, 1.67) 0.651
BMI categories, n (%)
Underweight 1.0
Normal weight 1.19 (0.70, 2.03) 0.526
Overweight 1.38 (0.80, 2.39) 0.251
Obese 1.35 (0.77, 2.37) 0.288
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Implications for practice
To help assess applicability and to enable clinicians to
replicate intervention strategies to improve health, re-
searchers can make use of available routinely collected
data in intervention studies in a relatively inexpensive
way. This would allow assessment of the representative-
ness of the study population compared with the target
population from which it was drawn and for whom the
intervention is planned. Detailed reporting of reasons
for exclusions and presentation of results by age, sex, so-
cioeconomic status and other important characteristics,
such as ethnic group, could help clinicians and policy-
makers to take more informed decisions on whether to
implement interventions.
Enrolment and retention or not in public health inter-
vention trials should be modelled carefully at every stage
of the research process from design through pilot and
definitive trial stages to the end of implementation [16].
In this way, barriers to participation and retention in tri-
als which often mirror barriers to implementation can
be understood and removed if possible at an early stage.
If barriers cannot be removed or the program benefits
cannot be effectively enhanced to overcome barriers,
then public health interventions can be abandoned or
redesigned before large amounts of public money are
spent on interventions that will not be effective for the
target population.
Conclusion
This study shows that the trial population who took part
in the Cessation in Pregnancy Incentives Trial (CPIT)
were representative of the target population of pregnant
smokers identified at maternity booking in the trial
catchment area in relation to important demographic
and clinical variables. This finding supports the view that
the effectiveness of the intervention examined in the
trial would be generalisable if offered to all pregnant
smokers identified in the trial area at maternity booking and
perhaps more widely. To underpin guidelines relevant to
the majority of the population that call for quality, efficient,
effective and holistic health care, trial participant representa-
tiveness to the target population should be examined along-
side internal validity in the ranking of evidence.
Acknowledgements
Mrs Lydia A. Yamoah: Principal of Midwifery and Health Care Assistants
Training College, Mampong Ashanti. Ghana. She contributed critically to the
drafting, fine tuning and proofreading the draft. Commonwealth
Commission UK for providing financial support to undertake the Master’s
degree program and the thesis project.
We would like to acknowledge the help and support of NHS Greater
Glasgow and Clyde R&D department, in particular Dr Roma Armstrong and
Brenda Colvin, without whose help this trial would not have been possible.
Funding
This study was funded by a grant from the Chief Scientist Office Scottish
Government CZH/4/594, Glasgow Centre for Population Health, NHS Greater
Glasgow and Clyde Endowments, the Royal Samaritan Endowment Fund
and Glasgow Children’s Hospital Charity.
Availability of data and materials
Raw data from this trial may be made available on request by Professor
Tappin.
Authors’ contributions
BB conceived the study, was involved in designing the study, data analyses
and drafting of the article. LB was involved in designing the study and
drafting the article. LS was involved in data acquisition and cleaning,
designing the study, and drafting and proofreading the article. DM was
involved in data cleaning, analyses and proofreading the article. WS was
involved in designing the study, and drafting and proofreading the article.
DT conceived the study, was involved in designing the study, and drafting
and proofreading the article. All authors read and approved the final
manuscript.
Authors’ information
1. Barnabas Bessing (field epidemiologist): WHO International STOP
Consultant.
Has extensive midwifery/nursing teaching and public health working
experience. Undertook this work as a Master’s thesis, and was involved in
design, data analyses, and writing the paper.
2. Linda Bauld (Co-principal Investigator): Professor of Health Policy,
University of Stirling and UK Centre for Tobacco and Alcohol Studies, has
extensive experience of quantitative work related to smoking cessation. She
supported the trial on a day-to-day basis and was involved in writing the
paper.
3. Lesley Sinclair (Trial Manager): has experience of data management and
the management of clinical trials. She ran the trial on a day-to-day basis,
assisted with study design, and data acquisition and cleaning for analyses.
4. Daniel F Mackay: Reader in Public Health, has extensive experience in
quantitative research work and data analyses. He assisted in the organisation,
analyses of the data and was involved in the supervision of the project work.
5. William Spence: University Teacher in Public Health, has extensive
experience in qualitative work and teaching. He was fully involved in the
project design, supervision, and in writing the paper.
6. David Tappin (Co-Principal Investigator): Professor of Clinical Trials for
Children is based at Glasgow University. He coordinated and managed the
overall running of the trial, fully supervised this project and was closely
involved in data analyses and in writing the paper.
Competing interests
The authors declare that they have no competing interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
The Cessation in Pregnancy Incentives Trial (CPIT) was approved by the NHS
West of Scotland Research Ethics Committee 2 (11/AL/0204) and a
substantial amendment granted by the NHS West of Scotland Research
Ethics Subcommittee 4 allowed anonymous use of routine data on nontrial
participants without direct patient consent. The Caldicott guardian also
granted approval for BB to use patient-level data without direct patient iden-
tifiers. Trial participants in CPIT gave individual consent.
Author details
1World Health Organization, Section of Expanded Programme on
Immunization, Ground Floor, UNECA building, Box 3069, Addis Ababa,
Ethiopia. 2Centre for Tobacco and Alcohol Studies, School of Health Sciences,
University of Stirling, Stirling FK9 4LA, UK. 3Institute of Health and Wellbeing,
Public Health, University of Glasgow, 1 Lilybank Gardens, Glasgow G12 8RZ,
Scotland, UK. 4School of Medicine, University of Glasgow, 1 Lilybank Gardens,
Glasgow G12 8RZ, Scotland, UK. 5Section of Child Health, School of Medicine,
Glasgow University, Scottish Cot Death Trust, West Glasgow Ambulatory
Hospital, Yorkhill, Glasgow G3 8SJ, UK.
Received: 27 July 2015 Accepted: 13 August 2016
Bessing et al. Trials  (2016) 17:426 Page 6 of 7
References
1. Travers J, Marsh S, Williams M, Weatherall M, Caldwell B, Shirtcliffe P, et al.
External validity of randomised controlled trials in asthma: to whom do the
results of the trials apply? Thorax. 2007;62:219–23.
2. Herland K, Akselsen JP, Skjønsberg OH, Bjermer L. How representative are
clinical study patients with asthma or COPD for a larger ‘real life’ population
of patients with obstructive lung disease? Respir Med. 2005;99:11–9.
3. Fortin M, Dionne J, Pinho G, Gignac J, Almirall J, Lapointe L. Randomized
controlled trials: do they have external validity for patients with multiple
comorbidities? Ann Fam Med. 2006;4:104–8.
4. Petersen MK, Andersen KV, Andersen NT, Soballe K. ‘To whom do the results
of this trial apply?’: external validity of a randomized controlled trial
involving 130 patients scheduled for primary total hip replacement. Acta
Orthop. 2007;78:12–8.
5. Antes G. The evidence base of clinical practice guidelines, health
technology assessments and patient information as a basis for clinical
decision-making. Z Arztl Fortbild Qualitatssich. 2004;98:180–4.
6. Le Strat Y, Rehm J, Le Foll B. How generalisable to community samples are
clinical trial results for treatment of nicotine dependence: a comparison of
common eligibility criteria with respondents of a large representative
general population survey. Tob Control. 2011;20:338–43.
7. Seale JP, Gebski VJ, Keech AC. Generalising the results of trials to clinical
practice. Med J Aust. 2004;181:558–60.
8. Jones R, Jones RO, McCowan C, Montgomery AA, Fahey T. The external
validity of published randomized controlled trials in primary care. BMC Fam
Pract. 2009;10:5.
9. Okuda M, Hasin DS, Olfson M, Khan SS, Nunes EV, Montoya I, et al.
Generalizability of clinical trials for cannabis dependence to community
samples. Drug Alcohol Depend. 2010;111:177–81.
10. Dawes M. Co-morbidity: we need a guideline for each patient not a
guideline for each disease. Fam Pract. 2010;27:1–2.
11. Flather M, Delahunty N, Collinson J. Generalizing results of randomized trials
to clinical practice: reliability and cautions. Clin Trials. 2006;3:508–12.
12. Yancey AK, Ortega AN, Kumanyika SK. Effective recruitment and retention of
minority research participants. Annu Rev Public Health. 2006;27:1–28.
13. Zimmerman M, Chelminski I, Posternak MA. Generalizability of
antidepressant efficacy trials: differences between depressed psychiatric
outpatients who would or would not qualify for an efficacy trial. Am J
Psychiatry. 2005;162:1370–2.
14. Hoertel N, Le Strat Y, De Maricourt P, Limosin F, Dubertret C. Are subjects in
treatment trials of panic disorder representative of patients in routine
clinical practice? Results from a national sample. J Affect Disord. 2013;146:
383–9.
15. Cole SR, Stuart EA. Generalizing evidence from randomized clinical trials to
target populations The ACTG 320 Trial. Am J Epidemiol. 2010;172:107–15.
16. Spoth R, Redmond C. Parent motivation to enroll in parenting skills
programs: A model of family context and health belief predictors. J Fam
Psych. 1995;9:294–310.
17. Tappin DM, Bauld L, Tannahill C, de Caestecker L, Radley A, McConnachie A,
et al. The Cessation in Pregnancy Incentives Trial (CPIT): study protocol for a
randomised controlled trial. Trials. 2012;13:113.
18. Tappin D, Bauld L, Purves D, Boyd K, Sinclair L, MacAskill S, et al. Financial
incentives for smoking cessation in pregnancy: randomised controlled trial.
BMJ. 2015;350:h134.
19. Boyd KA, Briggs AH, Bauld L, Sinclair L, Tappin D. Are financial incentives
cost-effective to support smoking cessation during pregnancy? Addiction.
2016;111(2):360–70. doi:10.1111/add.13160.
20. Director of Public Health, Greater Glasgow and Clyde NHS Board. Update
on progress with recommendations from the Director of Public Health
report: keeping health in mind. Board paper 12/52. 2014. http://library.
nhsggc.org.uk/mediaAssets/Board%20Papers/12-52.pdf page 6. Accessed 18
Feb 2015
21. National Institute of Health and Care Excellence: quitting smoking in
pregnancy and follow childbirth (PH26).2010. https://www.nice.org.uk/
guidance/PH26. Accessed 18 Feb 2015
22. Scottish Index of Multiple Deprivation 2012. http://simd.scotland.gov.uk/
publication-2012 Accessed 18 Feb 2015
23. Deveci SE, Deveci F, Acik Y, Ozan T. The Measurement of exhaled carbon
monoxide in healthy smokers and non-smokers. Respir Med. 2004;98:551–6.
24. Stata C. Stata Statistical Software Release 7.0: Programming: Stata
Corporation, 2001.
25. Frewen AR, Baillie AJ, Montebello ME. Are cannabis users who participate in
a randomized clinical trial different from other treatment seekers? J Subst
Abuse Treat. 2009;36:339–44.
26. Graham AL, Papandonatos GD, DePue JD, DePue JD, Pinto BM, Borrelli B, et
al. Lifetime characteristics of participants and non-participants in a smoking
cessation trial: implications for external validity and public health impact.
Ann Behav Med. 2008;35:295–307.
27. Howard-Pitney B, Fortmann SP, Killen JD. Generalizability of findings from a
chewing tobacco cessation clinical trial. Nicotine Tob Res. 2001;3:347–52.
28. Moore DA, Goodall RL, Ives NJ, Hooker M, Gazzard BG, Easterbrook PJ. How
generalizable are the results of large randomized controlled trials of
antiretroviral therapy? HIV Med. 2001;1:149–54.
29. Licht RW, Gouliaev G, Vestergaard P, Frydenberg M. Generalisability of
results from randomised drug trials. A trial on antimanic treatment. Br J
Psychiatry. 1997;170:264–7.
30. Van Spall HGC, Toren A, Kiss A, Fowler RA. Eligibility criteria of randomized
controlled trials published in high-impact general medical journals: a
systematic sampling review. JAMA. 2007;297:1233–40.
31. Usmani ZC, Craig P, Shipton D, Tappin D. Comparison of CO breath testing
and women’s self-reporting of smoking behaviour for identifying smoking
during pregnancy. Subst Abuse Treat Pr. 2008;3:4.
32. Kotz D, Fidler J, West R. Very low rate and light smokers: smoking patterns
and cessation-related behaviour in England, 2006–11. Addiction. 2012;
107(5):995–1002. doi:10.1111/j.1360-0443.2011.03739.x.
•  We accept pre-submission inquiries 
•  Our selector tool helps you to find the most relevant journal
•  We provide round the clock customer support 
•  Convenient online submission
•  Thorough peer review
•  Inclusion in PubMed and all major indexing services 
•  Maximum visibility for your research
Submit your manuscript at
www.biomedcentral.com/submit
Submit your next manuscript to BioMed Central 
and we will help you at every step:
Bessing et al. Trials  (2016) 17:426 Page 7 of 7
